Importantly, since PRMT5 inhibition enhances checkpoint immunotherapy in melanoma models (17), combining PRMT5 inhibitors with immunotherapy may provide a treatment option for patients who fail immunotherapy alone. This evidence concerns the gene PRMT5 and melanoma.